At 48 hours post-treatment, trypan blue assay showed that FLT3/ITD+ samples were sensitive to IB in similar doses to FLT3/ITD+ cell lines while FLT3/ITDneg samples were not, demonstrating that IB effectively targets more heterogeneous populations of primary FLT3/ITD+ AML cells (Fig. 6B). Here, FLT3 is linked to acute myeloid leukemia.